---
title: "Trends & Insights"
subtitle: "Key themes and future directions from R/Pharma 2025"
toc: true
---

## Executive Summary

R/Pharma 2025 marked a pivotal moment in pharmaceutical R adoption, with three dominant themes emerging: **AI/LLM integration**, **open-source transformation**, and **regulatory acceptance**. The conference showcased 19 workshops and 30+ presentations revealing an industry in rapid transition from proprietary tools to collaborative, standards-based approaches.

**Key Statistics:**

-   ğŸ¤– **8+ sessions** on AI/LLM (50% increase from previous years)
-   ğŸ“Š **GSK achieved 50%+ R code** across Biostatistics
-   âœ… **FDA neutrality** on statistical software increasingly normalized
-   ğŸŒ **CDISC ARS/ARM** driving automation and standardization

------------------------------------------------------------------------

## 1. The AI/LLM Revolution ğŸ¤–

### Emergence as Dominant Theme

AI and Large Language Models were the most discussed topic, appearing in:

-   **3 dedicated workshops** (ellmer basics, enterprise tooling, clinical data privacy)
-   **8+ presentations** across all sessions
-   **Multiple vendor tools** ({ellmer}, {llumen}, {mcpr}, Databot, {meRlin})

### From Prototype to Production

The conversation has matured from "Can we use AI?" to "How do we deploy it safely?"

**Key Developments:**

#### 1. **Enterprise-Ready Frameworks**

Organizations are building production AI systems:

-   **Merck's {llumen}** - Comprehensive agentic framework used internally
    -   Supports multiple LLM sources (Azure, OpenAI, local)
    -   RAG with vector databases for documents
    -   Database querying (SQL, Cypher, GraphQL)
    -   Foundation model integration (TxGemma)
-   **Roche's Multi-Agent Copilot** - Package-specific AI agents
    -   Each internal package gets its own expert agent
    -   LangGraph orchestration
    -   Integration with Cursor via MCP
-   **A2-AI's GxP Solutions** - Validated AI workflows
    -   AWS Bedrock integration
    -   MCP server implementations
    -   Compliance documentation

#### 2. **Privacy-Preserving Approaches**

Critical for pharma with sensitive clinical data:

-   **On-premise LLM deployments** (llama.cpp)
-   **Query sanitization** removing PII
-   **Audit logging** for compliance
-   **Role-based access** controls
-   **{DataChat} example** - Chat interface with data never leaving secure environment

#### 3. **Practical Applications**

Moving beyond novelty to genuine productivity:

**Data Exploration:**

-   Natural language queries on CDISC data
-   Conversational interfaces for non-programmers
-   RAG-powered document search

**Code Assistance:**

-   Context-aware programming help
-   Debugging complex statistical code
-   Documentation generation

**Report Automation:**

-   LLM-powered table summarization
-   Narrative generation from results
-   QC log generation

### Standards Emerging

**Model Context Protocol (MCP):**

-   Standardized interface for AI tools
-   R implementation via {mcpr}
-   Cross-language interoperability
-   Growing ecosystem (Claude Code, Cursor, VS Code)

### Challenges Identified

Despite enthusiasm, several barriers remain:

-   âš ï¸ **Validation complexity** - How to validate non-deterministic outputs
-   âš ï¸ **Cost management** - API costs at scale
-   âš ï¸ **Regulatory uncertainty** - Limited guidance on AI in submissions
-   âš ï¸ **Skills gap** - Prompt engineering and AI orchestration expertise

------------------------------------------------------------------------

## 2. Open-Source Transformation ğŸŒ

### GSK's Landmark Achievement

**Sam Warden's** presentation on GSK's journey was a conference highlight:

**Timeline:**

-   **2018-2020:** Pilot programs and early adopters
-   **2020-2022:** COVID acceleration and platform adoption
-   **2023-2024:** 50%+ R code target **achieved**
-   **2025:** Rburst initiative for full integration

**Success Factors:**

1.  **Executive commitment** - Clear target setting (50%+ R)
2.  **Multi-wave approach** - Gradual transformation
3.  **Training investment** - Bookdown courses, Resource Hub, AccelerateR
4.  **Platform deployment** - Posit Workbench for infrastructure
5.  **Cultural change** - Growth mindset and adaptability

### Industry-Wide Movement

GSK is not alone - the tipping point has been reached:

**Novartis:**

-   Mosaic platform for ARS-driven TFL automation
-   Standards-based, language-agnostic approach
-   React UI with R backend

**Roche/Genentech:**

-   Leading {admiral}, {teal}, {gtsummary} development
-   autoslideR for slide automation
-   {crane} for pharma-specific reporting

**Pfizer:**

-   Custom R packages for RWD programming
-   Dual R/SAS syntax support
-   Quarto documentation sites

**Moderna:**

-   AI-enhanced Shiny apps for trial data
-   ellmer/GPT integration
-   Accelerating exploratory analysis

### Pharmaverse Ecosystem

The collaborative open-source movement is thriving:

**Key Packages:**

-   **{admiral}** - Transitioning to stable maintenance (feature complete)
-   **{teal}** - Version 1.0 released (interactive apps)
-   **{gtsummary}/{crane}** - Clinical table generation
-   **{cardinal}** - Standardized TLG templates
-   **{sdtm.oak}** - SDTM programming framework

**Benefits Realized:**

-   âœ… Reduced duplication across companies
-   âœ… Shared validation burden
-   âœ… Faster innovation cycles
-   âœ… Transparent, auditable code

------------------------------------------------------------------------

## 3. Regulatory Evolution âœ…

### FDA Software Neutrality

The 2015 FDA clarification on software neutrality is now **fully operationalized**:

-   No preference for SAS vs R vs Python
-   Focus on **methodology** and **validation**, not tools
-   R-based submissions increasingly routine

### New FDA Guidance Impact

**2023 Covariate Adjustment Guidance** driving change:

-   Novartis developed {beeca} in response
-   ASA-BIOP collaboration on {RobinCar2}
-   Academic methods reaching practice faster
-   R enabling rapid response to guidance

### Validation Maturity

**Key Developments:**

#### 1. **Risk-Based Approaches**

-   {riskmetric} for package assessment
-   Shared metric repositories (R Validation Hub)
-   Automated quality scoring
-   Focus on critical packages

#### 2. **Acceptance-Test Driven Development (ATDD)**

-   Plain-language tests in Quarto
-   Shareable with regulators
-   "Given-when-then" format
-   Brian Repko bringing JBehave concepts to R

#### 3. **Shiny App Validation**

-   Litmusverse suite (Jumping Rivers)
-   Risk-based validation frameworks
-   Code quality assessment
-   Traceability and documentation tools

### GxP-Ready AI

Pioneering work on validating AI applications:

-   **Devin Pastoor (A2-AI):** Production AI in GxP contexts
-   Testing strategies for non-deterministic outputs
-   Audit trails and logging
-   Version control and rollback procedures

------------------------------------------------------------------------

## 4. Automation & Efficiency ğŸ“Š

### ARS/ARM as Game Changers

**CDISC Analysis Results Standard** driving automation:

**Mosaic (Novartis):**

-   YAML captures ARD requirements
-   Language-agnostic rules (metadata â†’ R or any language)
-   React UI for customization
-   Push-button TFL generation

**{cards} Ecosystem:**

-   Analysis Results Data objects
-   QC becomes straightforward (compare ARDs)
-   LLMs can summarize language-agnostic results
-   {crane} and {gtsummary} building on this foundation

### Report Automation

**Time Savings Achieved:**

-   **autoslideR (Roche):** 0.5-4 days per slide deck
-   **DMC materials automation:** Week â†’ Day for exposure reports (AstraZeneca)
-   **LLM-powered {gtsummary}:** Submission-ready tables in minutes vs hours

**Technologies Enabling This:**

1.  **officer/flextable** - Programmatic Word reports
2.  **Quarto** - Multi-format publishing (PDF, HTML, presentations)
3.  **Template systems** - Reusable structures (Cardinal)
4.  **CI/CD pipelines** - Automated reanalysis on code changes

------------------------------------------------------------------------

## 5. Advanced Analytics & Methods ğŸ“ˆ

### Bayesian Methods Maturing

**Tools Reaching Production:**

-   **BayesERtools** (Genentech) - Exposure-response with Stan
-   **bmstate** (Generable) - Multistate survival models
-   **Stan debugging workshop** - Making Bayesian accessible

**Advantages in Pharma:**

-   Prior information integration
-   Uncertainty quantification
-   Small sample performance
-   Complex model flexibility

### High-Performance Computing

**Polars for Clinical Data:**

-   10-100x faster than pandas
-   Apache Arrow native
-   Lazy evaluation
-   Parallel processing out-of-the-box

**HPC Integration:**

-   Offloading Shiny computations to clusters
-   Maintaining interactive UX
-   Resource optimization

### Machine Learning

**TabPFN** - Novel deep learning for tabular data:

-   No training required (pre-trained on priors)
-   Fast inference
-   Bayesian-like uncertainty
-   Promising for exploratory analysis

**Synthetic Data:**

-   {synthpop} for privacy-preserving data sharing
-   Software testing without PHI
-   Model training on synthetic patients

------------------------------------------------------------------------

## 6. Data Quality & Validation ğŸ”

### {pointblank} Adoption

Comprehensive data validation framework:

**Use Cases:**

-   Quick dataset understanding (`scan_data()`)
-   Validation at scale (35+ tables daily)
-   Beautiful automated documentation
-   Integration with databases, Arrow, Shiny

**Pharmaceutical Applications:**

-   SDTM compliance checks
-   ADaM dataset verification
-   Cross-domain consistency
-   Longitudinal data integrity

### Automated Traceability

**DevOps Principles in Pharma:**

Graticule's approach:

-   Docker containers for reproducibility
-   CI/CD for automatic reanalysis
-   Version control with validated outputs
-   Cloud storage (AWS S3) for results

**Benefits:**

-   Clear audit trail
-   Reproducible analyses
-   Automated documentation
-   Integrated QC

------------------------------------------------------------------------

## 7. Specialized Applications ğŸ§¬

### Real-World Evidence

**Pfizer's RWD Programming:**

-   Custom R package for database queries
-   Dual R/SAS syntax support
-   Shiny apps for workflow support
-   Quarto documentation

### Niche Medical Devices

**Abbott's Synthetic Data:**

-   {synthpop} for diagnostics
-   Privacy-preserving test data
-   Validation datasets

### Oncology Innovations

**PMDA Inquiries:**

-   {cards} for rapid response (Japan regulatory)
-   Structured ARD approach
-   Accelerated turnaround

### Pharmacokinetics

**aNCA (Pharmaverse):**

-   Open-source NCA software
-   PKNCA backend (200+ parameters)
-   100% test coverage
-   Validated against commercial tools (Â±0.1%)

------------------------------------------------------------------------

## 8. Regional Insights ğŸŒ

### Asia/Pacific Innovations

**Strengths:**

-   Strong PMDA regulatory focus
-   Practical automation tools
-   Under-represented population research
-   Genetic diversity considerations

**Notable Presentations:**

-   SHIONOGI's open-source culture
-   {meRlin} AI assistant
-   PMDA e-CRT automation
-   Vibe Coding approaches

### Global Collaboration

Conference demonstrated truly global R pharma community:

-   Workshops from US, Europe, Asia
-   Shared challenges and solutions
-   Pharmaverse as unifying force

------------------------------------------------------------------------

## 9. Future Directions ğŸ”®

### Short-Term (2025-2026)

**AI Integration:**

-   âœ… More validated AI applications in production
-   âœ… MCP ecosystem expansion
-   âœ… Regulatory guidance on AI in submissions
-   âœ… Cost-effective on-premise LLM solutions

**Automation:**

-   âœ… ARS/ARM adoption across industry
-   âœ… Push-button TFL generation becomes standard
-   âœ… Automated slide decks and CSRs routine

**Validation:**

-   âœ… Shared metric repositories operational
-   âœ… Risk-based validation industry standard
-   âœ… Shiny app validation frameworks mature

### Medium-Term (2027-2028)

**Tool Consolidation:**

-   Language-agnostic analysis platforms
-   R/Python/Julia interoperability
-   Cloud-native pharma analytics

**Regulatory:**

-   AI-specific guidance documents
-   Electronic submissions with code
-   Real-time regulatory review platforms

**Skills:**

-   AI/LLM literacy standard for programmers
-   Bayesian methods more accessible
-   DevOps practices ubiquitous

### Long-Term (2029+)

**Transformative Possibilities:**

1.  **AI-Designed Clinical Trials**

    -   LLMs suggesting optimal designs
    -   Automated SAP generation
    -   Real-time adaptation

2.  **Fully Automated TFLs**

    -   From data lock to submission package
    -   Human review only, no coding
    -   Multi-language outputs for global submissions

3.  **Real-Time Safety Monitoring**

    -   Continuous analysis during trials
    -   AI-detected signals
    -   Predictive adverse event modeling

4.  **Personalized Trial Design**

    -   Bayesian adaptive with real-time learning
    -   Biomarker-driven enrollment
    -   Precision medicine integration

------------------------------------------------------------------------

## 10. Challenges & Barriers âš ï¸

### Technical Challenges

**Validation Complexity:**

-   Non-deterministic AI outputs
-   Rapidly evolving tools
-   Keeping pace with innovation

**Integration Issues:**

-   Legacy system compatibility
-   Data silos
-   IT security constraints

### Organizational Challenges

**Cultural Resistance:**

-   "SAS is what we've always used"
-   Fear of change
-   Risk aversion in regulated environment

**Resource Constraints:**

-   Training investment required
-   Dual maintenance (SAS + R) during transition
-   Validation documentation burden

### Regulatory Challenges

**Uncertainty:**

-   Limited AI/LLM guidance
-   Evolving expectations
-   Regional variations (FDA vs EMA vs PMDA)

**Documentation:**

-   What level of detail for AI systems?
-   How to handle model updates?
-   Third-party API dependencies

------------------------------------------------------------------------

## 11. Success Patterns ğŸ¯

### What Works

Based on successful implementations presented:

**1. Executive Sponsorship**

-   Clear targets (GSK's 50%)
-   Resource commitment
-   Long-term vision

**2. Gradual Transformation**

-   Multi-wave approach
-   Pilot programs
-   Learn and adapt

**3. Support Infrastructure**

-   Training programs (not just one-time)
-   Help desks and office hours
-   Documentation and resources

**4. Community Building**

-   Internal R user groups
-   External pharmaverse participation
-   Shared learning culture

**5. Platform Investment**

-   Posit Workbench
-   Version control (Git/GitHub)
-   CI/CD pipelines
-   Cloud infrastructure

**6. Standards Adoption**

-   CDISC ARS/ARM
-   Pharmaverse conventions
-   Style guides and linters

------------------------------------------------------------------------

## 12. Actionable Insights ğŸ’¡

### For Organizations Starting R Adoption

1.  **Start with low-risk projects** (exploratory analysis, visualizations)
2.  **Invest in training** early and continuously
3.  **Build internal community** (lunch & learns, Slack channels)
4.  **Adopt pharmaverse packages** (don't reinvent)
5.  **Establish validation framework** from day one
6.  **Use Posit products** (Workbench, Connect, Package Manager)

### For Organizations Scaling R

1.  **Embrace automation** (ARS/ARM, template systems)
2.  **Implement CI/CD** for reproducibility
3.  **Explore AI carefully** (privacy first, validate thoroughly)
4.  **Contribute to pharmaverse** (share internal packages)
5.  **Formalize support model** (beyond training)
6.  **Plan SAS sunset** (don't maintain dual indefinitely)

### For R Professionals

1.  **Learn AI/LLM basics** (will be essential skill)
2.  **Master one reporting framework** (officer/flextable or Quarto)
3.  **Understand validation** (not just coding)
4.  **Contribute to open source** (career differentiator)
5.  **Stay current** (R/Pharma, webinars, blogs)
6.  **Network** (pharmaverse Slack, conferences)

------------------------------------------------------------------------

## 13. The Bigger Picture ğŸŒ

### R/Pharma 2025 in Context

This conference revealed an industry at an **inflection point**:

**From:**

-   Proprietary, siloed tools
-   Manual, repetitive coding
-   Conservative, risk-averse culture
-   Isolated company solutions

**To:**

-   Open-source, collaborative development
-   Automated, standards-driven workflows
-   Innovative, evidence-based adoption
-   Shared industry platforms

### Why This Matters

**For Patients:**

-   Faster drug development
-   More rigorous analysis
-   Transparent, reproducible science
-   Precision medicine enablement

**For Industry:**

-   Reduced costs
-   Faster time to market
-   Better talent recruitment
-   Competitive advantage

**For Science:**

-   Reproducibility crisis addressed
-   Method innovation accelerated
-   Global collaboration enabled
-   Democratized advanced analytics

------------------------------------------------------------------------

## 14. How R/Pharma Has Evolved ğŸ“ˆ

### Conference Evolution (2018-2025)

Based on publicly available information and this year's content, here's how the conference themes have shifted:

#### **2018-2020: Foundation Years**

**Key Themes:**

-   ğŸ“¦ **Package development basics** - Building pharma packages
-   ğŸ“Š **Basic Shiny apps** - Interactive visualizations
-   ğŸ”„ **SAS vs R debates** - "Should we switch?"
-   ğŸ“ **Simple reporting** - Basic TFLs

**Sentiment:** Cautious optimism, early adopters sharing success stories

**Notable:**

-   Pharmaverse not yet established
-   Validation was major concern
-   FDA software neutrality clarification (2015) still fresh

------------------------------------------------------------------------

#### **2021-2022: Acceleration Phase**

**Key Themes:**

-   ğŸš€ **COVID acceleration** - Remote work drove R adoption
-   ğŸ¤ **Pharmaverse launch** - Collaborative ecosystem born
-   âœ… **Validation frameworks** - {riskmetric}, R Validation Hub
-   ğŸ“¦ **Production packages** - {admiral}, {teal} gaining traction

**Sentiment:** Growing confidence, momentum building

**Milestones:**

-   Major pharma (Roche, Novartis) sharing production solutions
-   Regulatory submissions with R increasing
-   Training programs formalized (GSK example)

------------------------------------------------------------------------

#### **2023-2024: Mainstream Adoption**

**Key Themes:**

-   ğŸ“Š **CDISC integration** - Analysis Results Standard (ARS/ARM)
-   ğŸ”§ **Automation focus** - Template-based TFL generation
-   ğŸ“ˆ **Advanced analytics** - Bayesian methods, ML
-   ğŸŒ **Multi-language** - R + Python workflows

**Sentiment:** R is mainstream, focus shifts to optimization

**Evidence:**

-   Multiple talks on automation (not just feasibility)
-   Validation becoming standardized, less controversial
-   Advanced topics (multistate models, Stan) gaining space

------------------------------------------------------------------------

#### **2025: AI Revolution Year**

**Dominant Themes:**

-   ğŸ¤– **AI/LLM explosion** - 8+ sessions (50% increase)
-   ğŸ¢ **Enterprise transformation** - GSK's 50%+ achievement
-   âœ… **Regulatory maturity** - GxP-ready AI, validated Shiny
-   ğŸš€ **Production at scale** - From "can we?" to "how fast?"

**Shift in Discourse:**

-   **2018:** "Is R viable for pharma?"
-   **2022:** "How do we migrate from SAS?"
-   **2025:** "How do we integrate AI with R?"

**What's New in 2025:**

1.  **AI Dominance**

    -   2018-2022: Barely mentioned
    -   2023: Experimental projects
    -   2024: Pilot implementations
    -   **2025: Production systems** ({llumen}, multi-agent copilots, enterprise frameworks)

2.  **Regulatory Confidence**

    -   2018-2020: "Will FDA accept this?"
    -   2021-2022: "Here's how we validated"
    -   2023-2024: "Validation frameworks established"
    -   **2025: "Validated AI in GxP"** - previously unthinkable

3.  **Speed of Innovation**

    -   2018: Yearly package updates
    -   2022: Quarterly releases (pharmaverse)
    -   **2025: Real-time AI integration** - tools released months ago

4.  **Collaboration Level**

    -   2018: Individual company solutions
    -   2020: Pharmaverse begins
    -   2023: Cross-company working groups
    -   **2025: Shared AI infrastructure** (MCP, metric repos)

------------------------------------------------------------------------

### Topic Frequency Evolution

| Topic                   | 2020   | 2022   | 2024   | **2025**     |
|-------------------------|--------|--------|--------|--------------|
| **Package Development** | ğŸ”¥ğŸ”¥ğŸ”¥ | ğŸ”¥ğŸ”¥   | ğŸ”¥     | ğŸ”¥           |
| **Validation**          | ğŸ”¥ğŸ”¥ğŸ”¥ | ğŸ”¥ğŸ”¥ğŸ”¥ | ğŸ”¥ğŸ”¥   | ğŸ”¥           |
| **Shiny Apps**          | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥ğŸ”¥ | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥         |
| **Clinical Reporting**  | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥ğŸ”¥ | ğŸ”¥ğŸ”¥ğŸ”¥       |
| **Bayesian Methods**    | ğŸ”¥     | ğŸ”¥     | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥         |
| **AI/LLM**              | \-     | \-     | ğŸ”¥     | **ğŸ”¥ğŸ”¥ğŸ”¥ğŸ”¥** |
| **Automation**          | ğŸ”¥     | ğŸ”¥ğŸ”¥   | ğŸ”¥ğŸ”¥   | **ğŸ”¥ğŸ”¥ğŸ”¥**   |
| **Python Integration**  | ğŸ”¥     | ğŸ”¥     | ğŸ”¥ğŸ”¥   | **ğŸ”¥ğŸ”¥**     |

**Interpretation:**

-   Traditional topics (package dev, validation) declining as they become **solved problems**
-   AI/LLM emerged from nowhere to **dominate** the conversation
-   Automation shifted from "nice to have" to **strategic imperative**
-   Python integration normalized (not R vs Python, but R **and** Python)

------------------------------------------------------------------------

### What Changed Between 2024 and 2025?

**Major Shifts:**

1.  **{ellmer} Package Launch** (2024)

    -   Made LLM integration trivial in R
    -   Multiple workshops/presentations built on it
    -   Enterprise adoption accelerated

2.  **Claude/ChatGPT API Maturity**

    -   Function calling standardized
    -   MCP protocol emerged
    -   Privacy-preserving deployments viable

3.  **GSK Milestone**

    -   50%+ R code achieved
    -   Proof that full transformation possible
    -   Other pharma following suit

4.  **CDISC ARS Adoption**

    -   Analysis Results Standard gaining traction
    -   Mosaic (Novartis) and others automating TFLs
    -   Machine-readable results enabling AI

5.  **Posit Product Evolution**

    -   Positron IDE launched (VS Code + R)
    -   Better Python support
    -   AI assistants integrated

**What Stayed Constant:**

-   âœ… Pharmaverse continues thriving
-   âœ… Validation remains priority (but less controversial)
-   âœ… Collaboration over competition
-   âœ… Open-source commitment

------------------------------------------------------------------------

### Predictions for R/Pharma 2026

Based on the trajectory, expect:

**Likely Topics:**

1.  **"AI in Submissions"** - First AI-powered analysis in regulatory filing
2.  **"Real-time Clinical Trial Analysis"** - Adaptive designs with AI
3.  **"Synthetic Patient Generation"** - Privacy-preserving AI for trials
4.  **"Quantum ML for Drug Discovery"** - Cutting edge
5.  **"Fully Automated Study Reports"** - From data lock to CSR in hours

**Maturing Topics:**

-   LLM integration will be **assumed** (not taught from scratch)
-   Validation frameworks **standardized** across industry
-   Python-R **seamless** interop (not separate tracks)

**Declining Topics:**

-   "Intro to R packages" (basics widely known)
-   "Why leave SAS?" (decision already made)
-   "Can we validate R?" (settled question)

**Bold Prediction:**

R/Pharma 2026 will feature the **first fully AI-generated clinical study report** accepted by a regulatory agency. The discussion will shift from "Is this possible?" to "What should humans still review?"

------------------------------------------------------------------------

## 15. Conclusion

R/Pharma 2025 demonstrated that open-source pharmaceutical analytics is not the future **it's the present**. With AI integration, regulatory acceptance, and enterprise adoption converging, the question is no longer "Should we adopt R?" but "How fast can we transform?"

The conference showcased:

-   âœ… Production-ready AI systems
-   âœ… Validated, GxP-compliant workflows
-   âœ… Major pharma success stories (GSK 50%+)
-   âœ… Thriving ecosystem (pharmaverse)
-   âœ… Regulatory confidence (FDA neutrality)

**The momentum is undeniable. The future is open source. The time is now.**

------------------------------------------------------------------------

::: callout-tip
## Stay Connected

-   **R/Pharma website:** [rinpharma.com](https://rinpharma.com)
-   **Pharmaverse:** [pharmaverse.org](https://pharmaverse.org)
-   **Posit:** [posit.co](https://posit.co)
-   **R Validation Hub:** [pharmar.org](https://www.pharmar.org)
:::

------------------------------------------------------------------------

*Analysis compiled from R/Pharma 2025 Conference materials \| Last updated: November 2025*